In a report released today, Eliana Merle from Cantor Fitzgerald maintained a Buy rating on AnaptysBio Inc (ANAB), with a price target of $140. The company’s shares opened today at $70.55.
According to TipRanks.com, Merle is ranked 0 out of 5 stars with an average return of -12.2% and a 21.7% success rate. Merle covers the Healthcare sector, focusing on stocks such as Aerpio Pharmaceuticals Inc, CymaBay Therapeutics, and Galapagos NV.
AnaptysBio Inc has an analyst consensus of Strong Buy, with a price target consensus of $130, which is an 84.3% upside from current levels. In a report issued on March 12, J.P. Morgan also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Based on AnaptysBio Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $16.99 million. In comparison, last year the company earned revenue of $3 million and had a GAAP net loss of $6.86 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies.
